Pemphigus Disease and Area Index: Unmet needs in the real-world management of pemphigus.

Over the past few decades, a number of scoring instruments have been developed to assess the severity and activity of autoimmune bullous diseases (AIBDs) (Daneshpazhooh et al., 2019; Nili et al., 2020; Nili et al., 2021; Nili et al., 2022). The Pemphigus Disease Area Index (PDAI), developed by the International Pemphigus Definitions Group, is an easy-to-use, quick, and reliable method for determining pemphigus severity. As a reliable and effective tool in clinical trials, PDAI may also have some limitations and might require some revisions to be used on a daily basis. Here, we propose some recommendations to improve the use of PDAI in the clinical setting.

[1]  D. Murrell,et al.  Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab‐treated and rituximab‐naïve patients , 2022, Dermatologic therapy.

[2]  Mingfei Chen,et al.  Nail changes in pemphigus and bullous pemphigoid: A single-center study in China , 2022, Frontiers in Medicine.

[3]  S. Tavakolpour,et al.  Factors associated with the healing time of pemphigus vulgaris oral lesions: a prospective study. , 2022, Oral diseases.

[4]  S. Tavakolpour,et al.  Current status and prospects for the diagnosis of pemphigus vulgaris , 2021, Expert review of clinical immunology.

[5]  Amir Teimourpour,et al.  Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study , 2021, The Journal of dermatological treatment.

[6]  S. Tavakolpour,et al.  Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration , 2020, Dermatologic therapy.

[7]  R. Shokouhi Shoormasti,et al.  Intralesional injection of biosimilar rituximab in recalcitrant mucocutaneous lesions of patients with pemphigus vulgaris: A pilot study , 2020, Dermatologic therapy.

[8]  S. Tavakolpour,et al.  Rituximab monotherapy in mild pemphigus , 2020, The Journal of dermatological treatment.

[9]  R. Bergman,et al.  Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  Azin Mirzazadeh,et al.  Pathogenic and protective roles of cytokines in pemphigus: A systematic review. , 2020, Cytokine.

[11]  S. Tavakolpour,et al.  Paradoxical reaction to rituximab in patients with pemphigus: a report of 10 cases , 2020, Immunopharmacology and immunotoxicology.

[12]  S. Tavakolpour,et al.  Iranian guideline for rituximab therapy in pemphigus patients , 2019, Dermatologic therapy.

[13]  S. Tavakolpour,et al.  Trichloroacetic acid as a treatment for persistent oral mucosal lesions in pemphigus vulgaris. , 2019, Journal of the American Academy of Dermatology.

[14]  H. Shimizu,et al.  Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. , 2018, Journal of the American Academy of Dermatology.

[15]  Amir Teimourpour,et al.  Anagen hair loss, anti‐desmoglein 1, and pemphigus disease area index: a significant relationship? , 2017, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[16]  P. Giavedoni,et al.  Remission Time after Rituximab Treatment for Autoimmune Bullous Disease: A Proposed Update Definition , 2015, Skin Pharmacology and Physiology.

[17]  C. Chams‐Davatchi,et al.  Loss of normal anagen hair in pemphigus vulgaris , 2015, Clinical and experimental dermatology.

[18]  A. Troxel,et al.  Reliability and convergent validity of two outcome instruments for pemphigus. , 2009, The Journal of investigative dermatology.

[19]  A. Ghassabian,et al.  Nail changes in pemphigus vulgaris , 2008, International journal of dermatology.

[20]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[21]  M. Durdu,et al.  The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. , 2006, Journal of the American Academy of Dermatology.

[22]  S. Tavakolpour,et al.  Sixteen‐year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review , 2018, International immunopharmacology.